Catalyst pharmaceuticals

Dedicated to Making a Meaningful Difference in the Lives of Patients Suffering from Rare and Difficult to Treat Diseases

Forbes 2024 AMERICA'S MOST SUCCESSFUL SMALL COMPANIES

NASDAQ: CPRX

June 2024

BIOFLORIDA 2022 Company of the Year

Safe Harbor

This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All statements regarding our strategy, future operations, financial position, estimated revenues or losses, projected costs, prospects, plans, and objectives, other than statements of historical fact included in our filings with the U.S. Securities and Exchange Commission ("SEC"), are forward-looking statements. The language reflected in these statements only speaks as of the date that appears on the front cover of the presentation; the words "may," "will," "could," "would," "expect," "intend," "plan," "anticipate," "believe," "estimate," "project," "potential," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You should not place undue reliance on forward-looking statements. While we believe that we have a reasonable basis for each forward-looking statement that we make, we caution you that these statements are based on a combination of facts and factors currently known by us and projections of future events or conditions about which we cannot be certain. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect our business, particularly those mentioned in the "Risk Factors" section of our Annual Report on Form 10-K filed with the SEC, reporting our financial position and results of operations as of and for the year ended December 31, 2023, as well as our subsequent reports filed with the SEC. In addition, market and industry statistics contained in this presentation are based on information available to us that we believe is accurate. This information is generally based on publications that are not produced for purposes of securities offerings or economic analysis. All forward-looking statements speak only as of the date that appears on the front cover of the presentation or the date of this presentation. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Catalyst Pharmaceuticals

A Differentiated Growing Rare Disease Company

Commercial Excellence

Proven track record of successfully launching and commercializing innovative, rare, and best-in-class neurological medicines

Strategic Portfolio Expansion

Demonstrated success acquiring and integrating high-value, complimentary rare (orphan) CNS and adjacent rare (orphan) disease assets to drive strong and sustained growth

Highly Qualified Leadership Team

Decades of combined industry experience, with extensive expertise spanning neurology, rare diseases, operations, and new product launches

Strong Financial Position

Positive cash flow and strong revenue growth enable continued execution against strategic priorities including portfolio expansion to further drive growth

Growing Revenues With Diversified Portfolio

Focus on Rare Neurological and Epileptic Disorders

Proprietary Portfolio

Neuromuscular

FIRDAPSE® - rare neuromuscular disease

AGAMREE® - rare muscular dystrophy disease

Epilepsy

FYCOMPA® - epileptic seizures

Product Franchises

Neuromuscular	Epilepsy
FIRDAPSE® (amifampridine) Tablets 10 mg aGamree® (vamorolone) oral suspension 40mg/mL	Fycompa™ (perampanel) tablets CII 2mg · 4mg · 6mg · 8mg · 10mg · 12mg

Proven U.S. Commercial Capabilities

Neuromuscular Franchise

FIRDAPSE: Proprietary Flagship Product

Only U.S. Approved Treatment for Lambert Eaton Myasthenic Syndrome (LEMS)

FIRDAPSE® (amifampridine) Tablets 10mg
Orally Delivered Potassium Channel Blocker

Clinically Proven to Maintain Muscle Strength and Mobility
Most Patients Respond and Remain on Treatment

- Approved in the U.S. in November 2018
- Product launched in Q1 2019
- Approved in people ≥6 years of age
- Orphan Drug Exclusivity through 2025
- Strong intellectual property estate enhances durability
- IP protection to 2037
- Total of 9 patents: 6 Listed in the Orange Book

Lambert Eaton Myasthenic Syndrome (LEMS)

A Rare Neuromuscular Autoimmune Disease

Affects Nerve-Muscle Communication



Most affected

Sometimes affected

Least affected

May cause:

- Weakening of upper arms and shoulder muscles
- Severe, debilitating, and progressive weakness in the upper legs and hips

Life-threatening weakness in respiratory muscles in some patients

Causes Debilitating, Progressive Muscle Weakness and Fatigue

50% of people with LEMS have underlying cancer

Observed in ~3% of small cell lung cancer patients

Affects both women and men

O'Neill, J H, Murry, N M, Newson-Davis, J: (1988): The Lambert-Eaton myasthenic syndrome. A review of 50 cases: doi: 10.1093/brain/111.3.577

FIRDAPSE: Unlocking U.S. Market Potential

Addressing an Important Unmet Need

U.S. LEMS Prevalence: 3,600 Patients
Potential of up to 5,400 Patients[1]



LEMS Diagnosis Importance

Ensures proper treatment; LEMS is often misdiagnosed

Identifies other potential underlying conditions

Symptom management enhances patients' QoL

Helps prevent complications from muscle weakness

VGCC testing has been shown to improve diagnosis

Growth Opportunities

Expanded LEMS education for HCPs to testing/diagnosis, leading to more patients eligible for treatment

Convert diagnosed LEMS but not yet treated with FIRDAPSE

Increase indicated maximum daily dose to 100mg in adults and pediatric patients weighing more than 45kg on May 30, 2024

[1] Lambert Eaton Myasthenic Syndrome is Underrecognized in Small Cell Lung Cancer: An Analysis of Real-World Data; presented IASLC 2023 World Conference on Lung Cancer; authors: David Morrell, Benjamin Drapkin, Guy Shechter, Regina Grebla;[2] Includes 225 patients now deceased

FIRDAPSE: Expanding the Global Reach

Global Expansion Initiatives Underway

Japan: Potential First Approved LEMS Therapy

LEMS prevalence: ~1,200 people

DyDo Pharma to develop & market the product

PMDA accepted NDA 12/23; ~9-mth priority review

If approved, Japan launch is expected 1H 2025

Expect 10-year market exclusivity upon approval

Japan NDA acceptance expands Catalyst's territory rights*

APAC/LATAM

Seeking partners for commercialization

Canada: Commercially Available

Approved by Health Canada on July 31, 2020

Canadian LEMS Prevalence: ~300 people

KYE Pharmaceuticals has the exclusive license

Innovative drug data exclusivity to 2028

No drug application referencing data accepted before 2026

*Under the amendment to our FIRDAPSE® license agreement that added Japan to our territory, upon the acceptance of DyDo's NDA by the PMDA (Japanese regulatory agency), which occurred on December 18, 2023, our territory in which we have the right to seek to commercialize FIRDAPSE® has automatically expanded to include several countries in Asia and Latin America; Source Catalyst Pharmaceuticals 2023 10K

Duchenne Muscular Dystrophy (DMD)

Rare and Life-threatening Neuromuscular Disorder

Most common form of muscular dystrophy in children

Characterized by progressive muscle dysfunction leads to ambulation loss, respiratory failure, heart issues, and premature death

Manifests in early childhood, usually diagnosed between the ages of 3 & 5 years old

Standard treatment involves corticosteroids, often with significant side effects

High unmet need for treatments to restore function, slow progression, improve clinical outcomes, and enhance QoL

Steroids are the Foundation of DMD Therapy

Current steroids:

Severe short- and long-term adverse events preclude optimal treatment, leading patients/physicians to:

- Start steroids later/avoid steroids
- Prescribe suboptimal steroid treatment
- Discontinue therapy

Ideal steroid:

Efficacious with minimal AEs, encouraging physicians to start treatment early, allowing patients to comply with and remain in treatment at optimal doses long-term

AGAMREE: Addresses Need for Tolerable Steroid

Steroids are the Backbone of DMD Therapy

AGAMREE - Compelling Safety Profile

In Clinical Studies, Demonstrated[1]

Proven efficacy, tolerability, safety, & ease of use

Equivalent efficacy to prednisone

Potential of significant reduction of steroid-associated side effect burden when compared with another corticosteroid, with potential benefits for:

- Bone Health
- Growth
- Behavior

U.S. DMD patient prevalence: ~ 11,000 to 13,000

DMD diagnosis rate; typically occurs at ages 2 - 5 years

DMD patients treated with corticosteroids at some point

Currently treated DMD patients receive concomitant steroid treatment



[1]Guglieri M et al (2022). JAMA Neurol. 2022;79(10):1005-1014.doi:10.1001/jamaneurol.2022.2480; Mah JK et al (2022). JAMA NetwOpen.2022; e2144178.doi:10.1001/jamanetworkopen.2021.44178.; Guglieri M et al (2022) JAMA. doi:10.1001/jama.2022.4315;Heier CR et al (2019); Life Science Alliance DOI: 10.26508; Liu X et al (2020). Proc Natl Acad Sci USA 117:24285-24293

Catalyst pharmaceuticals

AGAMREE: U.S. Commercially Available

Treatment for Duchenne Muscular Dystrophy (DMD)

aGamree (vamorolone) oral suspension 40mg/mL

Not actual size.

Designations

Orphan Drug and Rare Pediatric Disease

Potential to Deliver Meaningful Near & Long-term Value Adding to Continued Growth Momentum

U.S. approved for treatment in DMD patients ≥ 2yrs in October 2023

May increase ambulation duration and mobility, improving QoL

Launched March 13, 2024

Expanded neuromuscular franchise with minimal incremental investment

Comprehensive Patient Assistance Program

Orphan drug designation offers 7 years of market exclusivity

Patents protection to 2040: 6 patents listed in the Orange Book

Acquired North America License from Santhera Pharmaceuticals, July 2023. North American territories consist of the U.S., Canada, and Mexico

Epilepsy Franchise

FYCOMPA® (perampanel) CIII

Established, First-in-Class Commercial Epilepsy Asset

Synergistic Neurology Expansion

Acquired U.S. rights in January 2023

Franchise teams fully engaged - May 2023

Neuromuscular Franchise call point overlap - 45%

Compelling product net revenue contribution

Seek to expand into rare epilepsy or other neuroscience adjacencies

FYCOMPA® is approved to treat:



*Taken with another antiseizure medication or alone for patients 4 years of age and older.

†Taken with another antiseizure medication for patients 12 years of age and older.

Catalyst pharmaceuticals

FYCOMPA: Broad Spectrum Efficacy

Only Non-Competitive AMPA Receptor Antagonist

Well-tolerated, minimal drug-drug interactions, and no contraindications

Simple once-a-day dosing

Long half-life, relieving the anxiety of breakthrough seizures if a dose is missed

>70% retention rate for adult patients

Seizure-freedom rate is ˜ 72% when used adjunctively

Patent exclusivity until at least May 2025

FYCOMPA has been designated in the U.S. as a federally-controlled substance (CIII). For Full Prescribing Information, including Boxed WARNING for FYCOMPA®, please visit www.fycompa.com.

Catalyst pharmaceuticals

FYCOMPA: Attractive Market Opportunity

Epilepsy - High Unmet Medical Need

Epilepsy is 4th most common neurological disorder after migraine, stroke and Alzheimer's disease[1]

- ~3.4M patients in the U.S. with active epilepsy and ~470K children[2]
- ~150,000 new patients per year in U.S.[3]
- ~30 - 40% of all people with epilepsy still fail to respond to treatment despite the availability of a wide variety of anti-seizure medications

Treatment for epilepsy is evolving into a precision medicine composed of a variety of well-defined rare epilepsies of genetic origin

Fycompa™

[1]England MJ, Liverman CT, Schultz AM, Strawbridge LM, eds. Epilepsy Across the Spectrum: Promoting Health and Understanding. Washington, DC: National Academies Press (US); 2012. [2]CDC Epilepsy Data and Statistics; Epilepsy Prevalence in the US (data as of 2015); [3]Examining the Economic Impact and Implications of Epilepsy, AJMC (US); 2020

Catalyst pharmaceuticals

Catalyst Pharmaceuticals Portfolio

Catalyst Pharmaceuticals Portfolio

	Preclinical	Phase 1	Phase 2	Phase 3	FDA Approved
FIRDAPSE [1 2 3] Lambert Eaton myasthenic syndrome					
FIRDAPSE Pediatric Label Expansion Lambert Eaton myasthenic syndrome					
FYCOMPA Epilepsy					
AGAMREE [3] Duchenne Muscular Dystrophy					
FIRDAPSE 100 mg Dose Expansion Lambert Eaton myasthenic syndrome					

[1] EAP= Expanded Access Program; ISI Investigator Sponsored IND

[2] Breakthrough Therapy Designation

[3] Orphan Drug Designation

Corporate Highlights

Sustained Product Portfolio Growth

Portfolio Performance Q1 2023 vs Q1 2024

Total Net Revenues ($ in Millions)



*Total revenues include License and Other Revenues of approximately $68,000 in Q1 24 and $62,000 in Q1 23.
**1Q 23 FYCOMPA Net Revenues only include sales beginning date of acquisition on January 24, 2023.

Catalyst pharmaceuticals

Q1 2024 Financial Highlights

For the Three Months Ended March 31, 2024 (*In thousands, except per share data*)	2024	2023	% Change
Net Product Revenue	$98,441	$85,304	15.4%
FIRDAPSE Net Product Revenue	$66,842	$57,526	16.2%
FYCOMPA Net Product Revenue	$30,425	$27,778	9.5%
AGAMREE Net Product Revenue	$1,174	N/A	N/A
GAAP Net Income	$23,275	$29,568	-21.3%
Non-GAAP Net Income**	$46,767	$46,805	-0.1%
GAAP Net Income Per Share – Diluted	$0.19	$0.26	-26.9%
Non-GAAP Net Income Per Share – Diluted**	$0.38	$0.41	-7.3%

** The non-GAAP financial measure included in this press release excludes from the calculation of net income (i) the expense associated with non-cash stock-based compensation, (ii) non-cash depreciation expense, (iii) non-cash amortization of intangible assets expense, and (iv) the provision for income taxes. Non-GAAP net income per share is calculated by dividing non-GAAP net income by the weighted average shares outstanding.

Strong Financial Position
Underscores Successful Execution

(Dollars In Millions)

Q1 2024 Results	
Cash Position as of March 31, 2024*	$310.4
Total Product Net Revenue Q1 2024	$98.4
AGAMREE: First 2 weeks of Q1 2024 launch	$1.2
Total Revenue Growth compared to Q1 2023	15.4%
Net Product Revenue Growth Increase	
FIRDAPSE Q1 2024 vs Q1 2023	16.2%
FYCOMPA Q1 2024 vs Q1 2023	9.5%



* On January 9, 2024, added $140.7 million to cash position, net resulting from equity raise.

Catalyst pharmaceuticals

Continued Drivers to Deliver Long-Term Value

	2023 Accomplishments	Anticipated 2024 Milestones
Catalyst pharmaceuticals	Launched inaugural ESG annual report	Published 2023 ESG annual report
	Expanded portfolio - 2 additional products	Pursuing strategic expansion and lifecycle plans
FIRDAPSE® (amifampridine) Tablets 10 mg	Expanded focus to SCLC LEMS patients	Pursuing global partnership expansion plans
	sNDA for 100mg maximum daily dose accepted	Received U.S. approval of expanded indicated 100mg daily dose on May 30, 2024
	NDA accepted by PMDA in Japan (DyDo)	Expect a 9-month PMDA review period in Japan
	Received two new patent issuances	Continue to seek opportunities to enhance IP estate
aGamree® (vamorolone) oral suspension 40mg/mL	Acquired July 2023: FDA approved October 2023	Commenced U.S. commercial launch March 13, 2024; continue to advance launch initiatives
Fycompa™ (perampanel) tablets C 2mg · 4mg · 6mg · 8mg · 10mg · 12mg	Acquired Jan 2023: Completed U.S. team integration May 2023	

Strategic Growth Initiatives

Building on the Momentum

Expand Commercial Footprint	Explore commercial add-on assets both in the U.S. and globally Synergistic expertise to foster innovations Harness operational capabilities and industry expertise
Expand Portfolio in Rare & Orphan Diseases	Seek partnerships to accelerate growth into new therapeutic areas and larger markets focused on complimentary rare (orphan) CNS and adjacent rare (orphan) disease opportunities Geographical expansion of our portfolio products
Invest in Portfolio Diversification	Strong balance sheet reinforces executing on attractive opportunities Well-positioned to achieve long-term growth

Catalyst pharmaceuticals

NASDAQ: CPRX

Catalyst pharmaceuticals